Table 4.
Changes of Exploratory Endpoints After 26 Weeks of Treatment With Liraglutide, Sitagliptin, or Insulin Glargine in Combination With Metformin
| Exploratory endpoints | Liraglutide (n = 24) | Sitagliptin (n = 27) | Insulin glargine (n = 24) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Before treatment | After treatment | Change (Δ) | Before treatment | After treatment | Change (Δ) | Before treatment | After treatment | Change (Δ) | |
| PRL (μIU/mL) | 144.37 ± 56.58* | 220.15 ± 131.07 | 8.63 (−10.38, 90.35) | 143.14 ± 95.55* | 213.19 ± 179.65 | 4.09 (−14.29, 97.09) | 138.01 ± 44.85 | 148.08 ± 79.32 | 0 (−34.6, 29.47) |
| IL‐6 (pg/mL) | 2.61 ± 1.93* | 1.39 ± 1.30 | 0 (−3.78, 0.13) | 2.59 ± 2.45 | 1.39 ± 0.99 | 0 (−2.82, 0.51) | 2.39 ± 2.13 | 2.10 ± 1.78 | 0 (−0.68, 1.03) |
| Adiponectin (mg/mL) | 10.81 ± 9.89* | 17.77 ± 5.36 | 3.82 (0, 8.73) | 10.34 ± 10.40 | 13.39 ± 9.85 | 1.09 (−0.23, 8.28) | 14.75 ± 9.18 | 13.57 ± 9.34 | 0.33 (−1.71, 5.06) |
| HOMA‐IR | 9.23 ± 9.03* | 4.99 ± 3.31 | −2.19 (−5.04, −0.52) | 6.47 ± 6.43 | 5.25 ± 4.46 | −1.04 (−2.63, −0.35) | 7.29 ± 7.02 | 5.70 ± 3.36 | −0.77 (−3.40, 1.69) |
| FIB‐4 | 0.79 ± 0.31 | 0.81 ± 0.32 | 0 (−0.12, 0.17) | 0.98 ± 0.42 | 0.86 ± 0.32 | −0.12 (−0.24, 0.09) | 1.10 ± 0.62 | 1.11 ± 0.35 | 0 (−0.12, 0.19) |
| NFS | −0.78 ± 0.81 | −0.69 ± 0.68 | 0.03 (−0.26, 0.52) | −1.55 ± 0.78 | −1.57 ± 0.65 | −0.07 (−0.41, 0.35) | −0.95 ± 0.85 | −0.86 ± 0.84 | 0 (0.30, 0.51) |
Abbreviations: FIB‐4, fibrosis‐4 index; HOMA‐IR, homeostatic model assessment of insulin resistance; IL‐6, interleukin 6; NFS, NAFLD Fibrosis Score; PRL, prolactin.
*
P < 0.05, comparison of data between groups before treatment and after treatment.